phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Beyond High-Dose IL-2: A novelTIL Expansion Platform Improves Safety and Efficacyof TIL Therapyina Preclinical Study

Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has emerged as a powerful immunotherapy for solid tumors, yet its broader application is constrained by reliance on high-dose interleukin-2 (IL-2), a cytokine that activates T cells but also drives T-cell exhaustion and causes severe toxicity.

July 3, 2026


July 15 2026

July 14 2026

July 13 2026

July 12 2026

July 10 2026

July 9 2026

July 8 2026

July 7 2026

July 6 2026

July 3 2026

July 2 2026

July 1 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy